Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance

CNS Pharmaceuticals, Inc.

Hearing held April 18, 2024; panel grants extension until July 15, 2024.
Must demonstrate compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)).
Company intends to implement its plan to meet the milestones set by the Panel.
Failure to comply by July 15 could result in delisting from Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.